RxDoctor Payments Data

Layla Lundquist-Smith, MD

Family Medicine · Atmore, ALNPI 1538452073

Payments from drug & device makers

$958in general payments, 2019–2025

Across 46 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$368
  • AbbVie$225
  • Amgen$101
  • Esperion Therapeutics, Inc.$74
  • Johnson & Johnson$57
  • Dexcom, Inc.$43
  • plus $91 from 5 others

What the payments were for

  • Food & beverage$958100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$958 in reported general payments places this provider in the 55th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$15,519
Medicare patients
61
Services billed
217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide103$139,995
JardianceEmpagliflozin52$75,219
EliquisApixaban92$65,657
MounjaroTirzepatide53$59,828
RybelsusSemaglutide22$28,192
TrulicityDulaglutide24$23,619
LinzessLinaclotide24$23,491
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$21,697
Tresiba Flextouch U-200Insulin Degludec29$20,559
JanuviaSitagliptin Phosphate14$11,237
Tresiba Flextouch U-100Insulin Degludec21$11,116
FarxigaDapagliflozin Propanediol17$9,776
Lantus SolostarInsulin Glargine,hum.Rec.Anlog54$8,535
Breo ElliptaFluticasone/Vilanterol17$6,647
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen280$5,956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$368$168,187125 claims
Lilly USA, LLCMounjaro, Trulicity$14$83,44777 claims
AbbVieLinzess$225$23,49124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Atmore

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →